These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39168104)

  • 21. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
    Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
    Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
    Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
    J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic changes in circulating PD-1
    Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
    Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137
    Ugolini A; Zizzari IG; Ceccarelli F; Botticelli A; Colasanti T; Strigari L; Rughetti A; Rahimi H; Conti F; Valesini G; Marchetti P; Nuti M
    EBioMedicine; 2020 Dec; 62():103098. PubMed ID: 33166793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
    Chen D; Barsoumian HB; Fischer G; Yang L; Verma V; Younes AI; Hu Y; Masropour F; Klein K; Vellano C; Marszalek J; Davies M; Cortez MA; Welsh J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.
    Murata D; Azuma K; Murotani K; Kawahara A; Nishii Y; Tokito T; Sasada T; Hoshino T
    Cancer Immunol Immunother; 2024 Sep; 73(11):214. PubMed ID: 39235457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of PD-1 and TIM-3 Ameliorates CD8
    Jin T; Gao F; Wang L
    Cell Biochem Biophys; 2024 Sep; 82(3):2759-2766. PubMed ID: 38995531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 34. METTL14 regulates CD8
    Sun C; Wang J; Li H; Liu L; Lin Y; Zhang L; Zu X; Zhu Y; Shu Y; Shen D; Wang Q; Liu Y
    World J Surg Oncol; 2024 May; 22(1):128. PubMed ID: 38725005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
    Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.
    Hummelink K; van der Noort V; Muller M; Schouten RD; van den Heuvel MM; Thommen DS; Smit EF; Meijer GA; Monkhorst K
    PLoS One; 2024; 19(7):e0293707. PubMed ID: 39083541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
    Hladíková K; Partlová S; Koucký V; Bouček J; Fonteneau JF; Zábrodský M; Tachezy R; Grega M; Špíšek R; Fialová A
    Oral Oncol; 2018 Jul; 82():75-82. PubMed ID: 29909905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.